mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases ASX: MSB; Nasdaq: MESO Operational Highlights and Financial Results for the Quarter Ended December 31, 2022 February 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance ...